BTIG analyst Sung Ji Nam raised her price target on Thermo Fisher to $320 and kept her Buy rating after the company raised its 3-year organic revenue growth projections to 5%-7% for the "first time in recent history". The analyst cites the company's rise in exposure to the faster growing segments within biopharma and emerging markets, reflecting the management's strategic R&D investments, M&A, and operational efficiency efforts. Sung Ji Nam adds that her price target assumes a 24-times forward earnings multiple and marks a 7% premium to Thermo Fisher's peer group average, with added upside coming from the company's capital deployment potential.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here